Interferon-γ and cancer immunoediting

Immunologic Research

Volumn 32, Issue 1-3, 2005, Pages 231-245

  Dunn, Gavin P ^a   Ikeda, Hiroaki ^a   Bruce, Allen T ^a   Koebel, Catherine ^a   Uppaluri, Ravi ^a   Bui, Jack ^a   Chan, Ruby ^a   Diamond, Mark ^a   White, J Michael ^a   Sheehan, Kathleen C F ^a   Schreiber, Robert D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cancer immunoediting; Immunosurveillance; Interferon ; Lymphocytes; Signal transduction

Indexed keywords

GAMMA INTERFERON; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ANTIGEN PRESENTATION; BREAST TUMOR; CANCER; CANCER IMMUNOTHERAPY; CARCINOGENESIS; GENE TARGETING; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSURVEILLANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR REJECTION;

ANIMALS; GENES, P53; GRAFT REJECTION; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; LYMPHOCYTES; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; MONITORING, IMMUNOLOGIC; NEOPLASM TRANSPLANTATION; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23844446653     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:32:1-3:231     Document Type: Review

References (63)

1. Bach EA, Aguet M, Schreiber RD: The IFN-γ receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15:563-591.
2. Schreiber GH, Schreiber RD: Interferon-γ; in The Cytokine Handbook, 4th ed. New York, Elsevier Science, 2003.
3. Weber-Nordt RM, Riley JK, Greenlund AC, Moore KW, Darnell JE, Schreiber RD: Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J Biol Chem 1996;271:27,954-27,961.
4. Riley JK, Takeda K, Akira S, Schreiber RD. Interleukin-10 receptor signaling through the JAK-STAT pathway: requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem 1999;274:16, 513-16,521.
5. Weaver BK, Bohn E, Gil MP, Judd BA, Sheehan KCF, Schreiber RD: TIGER (ABIN-3) is an IL-10 regulated inhibitor of NF-κB activation. 2004, submitted.
6. Ikeda H, Old LJ, Schreiber RD: The roles of IFN-γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002;13:95-109.
7. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
8. Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-360.
9. Dunn GP, Old LJ, Schreiber RD: The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-148.
10. Dighe AS, Richards E, Old LJ, Schreiber RD: Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors. Immunity 1994;1:447-456.
11. Dighe AS, Campbell D, Hsieh CS, Murphy KM, Schreiber RD: Tissue specific targeting of cytokine unresponsiveness in transgenic mice. Immunity 1995;3:657-666.
12. Dighe AS, Farrar MA, Schreiber RD: Inhibition of cellular responsiveness to interferon-γ (IFNγ) induced by overexpression of inactive forms of the IFNγ receptor. J Biol Chem 1993;268:10,645-10,653.
13. Huang S, Hendriks W, Althage A, et al: Immune response in mice that lack the interferon-γ receptor. Science 1993;259:1742-1745.
14. Meraz MA, White JM, Sheehan KCF, et al: Targeted disruption of the STAT1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996;84:431-442.
15. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD: Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-7561.
16. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-1111.
17. Bruce AT, Dunn GP, Ikeda H, Schreiber RD: A molecular explanation for IFN-γ's anti-tumor actions: increased tumor cell recognition and elimination by T cells. 2004, submitted.
18. Thomas L: Discussion; in Lawrence HS (ed): Cellular and Humoral Aspects of the Hypersensitive States. New York, Hoeber-Harper, 1959, pp 529-532.
19. Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27.
20. Thomas L: On immunosurveillance in human cancer. Yale J Biol Med 1982;55:329-333.
21. Stutman O: Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974;183:534-536.
22. Hunig T: T-cell function and specificity in athymic mice. Immunol Today 1983;4:84-87.
23. Maleckar JR, Sherman LA: The composition of the T cell receptor repertoire in nude mice. J Immunol 1987;138:3873-3876.
24. Ikehara S, Pahwa RN, Fernandes G, Hansen CT, Good RA: Functional T cells in athymic nude mice. Proc Natl Acad Sci USA 1984;81:886-888.
25. Herberman RB, Holden HT: Natural cell-mediated immunity. Adv Cancer Res 1978;27:305-377.
26. Heidelberger C: Chemical carcinogenesis. Annu Rev Biochem 1975;44:79-121.
27. Kouri RE, Nebert DW: Genetic Regulation of susceptibility to polycyclic-hydrocarbon-induced tumors in the mouse; in Hiatt HH, Watson JD, Winsten JA (eds): Origins of Human Cancer. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1977, pp 811-835.
28. Shinkai Y, Rathbun G, Lam KP, et al: RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992;68:855-867.
29. Uppaluri R, Dunn GP, Old LJ, Schreiber RD: IFNγ receptor-STAT1 signaling and cancer immunoediting; in Seghal PB, Levy DD, Hirano T (eds): Signal Transducers and Activators of Transcription: Activation and Biology. New York, Kluwer Academic, 2003, pp 399-418.
30. Chan SR, Bruce AT, Cardiff RD, Schreiber RD: Characterization of mammary adenocarcinomas that develop spontaneously in aged STAT1-deficient mice. 2004, submitted.
31. Schreiber RD, Old LJ, Hayday AC, Smyth MJ: Response to 'A cancer immunosurveillance controversy.' Nat Immunol 2004;5:4, 5.
32. Birkeland SA, Storm HH, Lamm LU, et al: Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995;60:183-189.
33. Penn I: Sarcomas in organ allograft recipients. Transplantation 1995;60:1485-1491.
34. Penn I: Malignant melanoma in organ allograft recipients. Transplantation 1996;61:274-278.
35. Sheil AGR: Cancer in dialysis and transplant patients; in Morris PJ (ed): Kidney Transplantation, vol 5. Philadelphia, WB Saunders, 2001, pp 558-570.
36. MacKie RM, Reid R, Junor B: Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003;348:567, 568.
37. Elder GJ, Hersey P, Branley P: Remission of transplanted melanoma - clinical course and tumour cell characterisation. Clin Transplant 1997;11:565-568.
38. Suranyi MG, Hogan PG, Falk MC, et al: Advanced donor-origin melanoma in a renal transplant recipient: immunotherapy, cure, and retransplantation. Transplantation 1998;66:655-661.
39. Clark WH Jr, Elder DE, Guerry DT, et al: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-1904.
40. Mihm MC Jr, Clemente CG, Cascinelli N: Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996;74:43-47.
41. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-1310.
42. Zhang L, Conejo-Garcia JR, Katsaros D, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
43. Naito Y, Saito K, Shiiba K, et al: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-3494.
44. Schumacher K, Haensch W, Roefzaad C, Schlag PM: Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-3936.
45. Knuth A, Danowski B, Oettgen HF, Old LJ: T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci USA 1984;81:3511-3515.
46. Darnell RB: Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA 1996;93:4529-4536.
47. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB: Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998;4:1321-1324.
48. Wheelock EF, Weinhold KJ, Levich J: The tumor dormant state. Adv Cancer Res 1981;34:107-140.
49. Uhr JW, Tucker T, May RD, Siu H, Vitetta ES: Cancer dormancy: studies of the murine BCL1 lymphoma. Cancer Res 1991;51:5045s-5053s.
50. Smyth MJ, Crowe NY, Godfrey DI: NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001;13:459-463.
51. Girardi M, Oppenheim DE, Steele CR, et al: Regulation of cutaneous malignancy by gammadelta T cells. Science 2001;294:605-609.
52. Street SE, Cretney E, Smyth MJ: Perform and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192-197.
53. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA: Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000;192:755-760.
54. Street SE, Trapani JA, MacGregor D, Smyth MJ: Suppression of lymphoma and epithelial malignancies effected by interferon γ. J Exp Med 2002;196:129-134.
55. Enzler T, Gillessen S, Manis JP, et al: Deficiencies of GM-CSF and interferon γ link inflammation and cancer. J Exp Med 2003;197:1213-1219.
56. van den Broek MF, Kagi D, Ossendorp F, et al: Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996;184:1781-1790.
57. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM: Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res 2000;6:3621-3628.
58. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ: Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002;168:1356-1361.
59. Takeda K, Smyth MJ, Cretney E, et al: Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161-169.
60. Smyth MJ, Thia KY, Street SE, et al: Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-668.
61. Noguchi Y, Jungbluth A, Richards E, Old LJ: Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA 1996;93:11,798-11,801.
62. Hayakawa Y, Rovero S, Forni G, Smyth MJ: Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci USA 2003;100:9464-9469.
63. Hayashi T, Faustman DL: Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Res 2002;62:24-27.